A Single Dose Study of LY2189265 in Subjects With Varying Degrees of Hepatic (Liver) Impairment

NCT01253304 · Completed

Last updated 2026-05-28

This clinical trial tested a single dose of the medication LY2189265 in adults with type 2 diabetes who had varying levels of liver function.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Non-randomized, open-label (no blinding) treatment study

Participants 26 people

Who can join Ages 18–85 · all sexes Healthy volunteers accepted.

Timeline Started 2010-11 · est. completion 2011-11

Where 2 sites · Germany, Hungary

What this study is testing ClinicalTrials.gov NCT01253304 ↗

Description as written by the study sponsor.

The primary purpose of this study is to help answer the following research questions, and not to provide treatment for any condition: * To evaluate how much of the study drug (LY2189265) is in the blood of participants with varying degrees of liver impairment compared to those with normal liver function. * To assess the safety of LY2189265 and any side effects that might be associated with it.

Treatments tested

LY2189265 also known as Dulaglutide Drug

Subcutaneous (SC) injection

Main thing measured	Pharmacokinetics: Maximum Observed Concentration (Cmax)
Sponsor	Eli Lilly and Company
Conditions studied	Diabetes Mellitus, Type 2
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT01253304 ↗